应用MTT法检测了靶向性药物索拉非尼(Sorafenib)分别与阿霉素(ADM)、氟尿嘧啶(5-FU)、顺铂(DDP)和紫杉醇(PTX)等4种化疗药物按照不同给药序贯联合作用对肝癌细胞Bel-7402增殖的影响。结果表明, 索拉非尼与4种化疗药物联用对Bel-7402细胞增殖的抑制作用效果均要好于单独用药, 对细胞的IC50明显低于单独用药。联合用药效果受到给药序贯的影响, 索拉非尼先于化疗药物给药, CI值(除与紫杉醇联用)均大于1, 表现为拮抗效应; 索拉非尼后于化疗药物给药, CI值均小于1, 表现为明显的协同效应。研究结果可供肝癌临床治疗参考, 有助于临床降低用药剂量, 减轻药物毒副作用。

The inhibitory effects of sorafenib combining with different concentrations of adriamycin, fluorouracil, cisplatin and paclitaxel in different sequences on the proliferation of Bel-7402 cells were evaluated by MTT assay. The results indicated that the inhibitory effect of cytotoxic drug combined with sorafenib was better than that of cytotoxic drug treatment alone, the IC50 decreased significantly. The antiproliferative effects of drug combination were affected by different drug sequences. The respective IC50 of sorafenib and cytotoxic drugs decreased when sorafenib used before cytotoxic drugs, while the CI values were all more than 1 (except paclitaxel group), which indicated an antagonistic effect. In contrast, when sorafenib used after cytotoxic drugs, the respective IC50 of drugs decreased more remarkably and the CI values were all less than 1, which indicated a significant synergistic effect. These results provided helpful information for hepatocellular carcinoma clinical therapy, they could conduce to less doses and toxic effects in clinical application.